Dectin-1 signaling drives pancreatic oncogenesis by inducing macrophage-mediated adaptive immune suppression
Dectin-1 信号传导通过诱导巨噬细胞介导的适应性免疫抑制来驱动胰腺肿瘤发生
基本信息
- 批准号:10359672
- 负责人:
- 金额:$ 38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-12-15 至 2023-11-30
- 项目状态:已结题
- 来源:
- 关键词:Adaptor Signaling ProteinAffinityAntifungal AgentsAntigensBindingBiochemicalC-Type LectinsCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCellsDataDevelopmentDiseaseDisease OutcomeDisease ProgressionEpithelialEpithelial CellsFamilyGalactose Binding LectinGalactosidesGrowthHumanImmuneImmune ToleranceImmune responseImmunosuppressionImmunotherapeutic agentImmunotherapyIncidenceInflammationInflammatoryInnate Immune ResponseInterruptionInvestigationInvestigational TherapiesLectinLigandsLigationMalignant NeoplasmsMediatingMusMutationMyeloid CellsMyeloid-derived suppressor cellsOncogenicOutcomePancreatic Ductal AdenocarcinomaPathologicPatientsPattern recognition receptorPhenotypePopulationRegimenRegulationRegulatory T-LymphocyteRoleSignal TransductionSterilitySurvivorsT cell anergyT cell differentiationT-LymphocyteTestingTherapeuticTumor-associated macrophagesWorkadaptive immunityadverse outcomeanergybasebeta-Glucanscancer subtypescheckpoint receptorscytotoxic CD8 T cellsdectin 1effector T cellimmunogenicimmunosuppressive macrophagesin vivomacrophagemembermortalitymouse modelnovelnovel strategiespancreatic ductal adenocarcinoma modelpancreatic neoplasmpancreatic tumorigenesispathogenic funguspromoterrecruitsynergismtumortumor microenvironmenttumor progressiontumorigenesistumorigenic
项目摘要
Summary
Pancreatic ductal adenocarcinoma (PDA) is an aggressive disease with few survivors. Progression of pancreatic
oncogenesis requires immune-suppressive inflammation in cooperation with oncogenic mutations. However, the
drivers of tumor-promoting inflammation in PDA are poorly understood. Dectin-1 is a member of the C-type Lectin
family of pattern recognition receptors and is required for the innate immune response to fungal pathogens. However,
Dectin-1 does not have an established role in sterile inflammation or in promoting oncogenesis. Non-pathogen-
derived Dectin-1 ligands have not been well-characterized. Our preliminary data showed that Dectin-1 in highly
expressed in both the inflammatory and epithelial compartments in PDA in mice and humans. Moreover, Dectin-1
ligation accelerated PDA development whereas Dectin-1 deletion was protective. Further, we discovered that
Galectin-9, a lectin with affinity for β-galactosides, is ubiquitous within the PDA tumor microenvironment and avidly
ligates Dectin-1. Mechanistically, we found that Dectin-1 signaling in tumor-associated macrophages (TAMs)
induces their reprogramming into immune-suppressive M2-like macrophages leading to Th2 and Treg
differentiation of CD4+ T cells in vivo. Based on these data, we postulate that Dectin-1 ligation of Galectin-9 is
a pivotal switch which drives immune-suppression in the pancreatic TME. In Aim 1 we will determine the
consequences of Dectin-1 activation in PDA and test whether targeting Dectin-1 or Galectin-9 are protective and
extend survival in diverse murine models of PDA. We will also determine the specific compartment (epithelial vs
inflammatory) in which Dectin-1 signaling is oncogenic. In Aim 2 we will test our overriding hypothesis is that
Dectin-1 signaling in myeloid cells induces the differential expansion of immune-suppressive macrophage subsets
which have the proclivity to generate pro-tumorigenic T cells leading to tumor-permissive anergy. We also will
delineate the biochemical mechanism of Dectin-1-dependant adaptive immune anergy in PDA and test our
translational hypothesis that targeting Dectin-1 will have synergistic efficacy with checkpoint-receptor directed
immunotherapeutic regimens. Collectively, Aim 2 will define the cellular and biochemical mechanisms of Dectin-
1 promotion of PDA and provide guidance for the development of novel strategies for experimental therapeutics.
Aim 3 will be dedicated to elucidating the immune-suppressive effects of Dectin-1 signaling in human PDA and
studying the implications of the Dectin-1–Galectin-9 axis on suppression of adaptive immunity and clinico-
pathologic disease features and outcome in patients. We anticipate that Dectin-1 activation via Galectin-9 is a
principal driver of immune-suppressive myeloid cell programming in PDA leading to CD4+ and CD8+ T-cell anergy.
We believe our work has high translational value and will suggest that Dectin-1 and Galectin-9 may be attractive
targets for experimental therapy in patients. Moreover, this work is likely to have far-reaching implications for a role
for Dectin-1 in other cancer subtypes and in sterile inflammation.
总结
胰腺导管腺癌(PDA)是一种侵袭性疾病,很少有幸存者。胰腺癌进展
肿瘤发生需要免疫抑制性炎症与致癌突变协同作用。但
PDA中促肿瘤炎症的驱动因素知之甚少。Dectin-1是C型凝集素家族的一员
是模式识别受体家族的成员,是对真菌病原体的先天免疫应答所必需的。然而,在这方面,
Dectin-1在无菌性炎症或促进肿瘤发生中没有确定的作用。非病原体-
衍生的Dectin-1配体尚未得到充分表征。我们的初步数据显示,Dectin-1在高水平
在小鼠和人的PDA的炎症和上皮区室中表达。此外,Dectin-1
连接促进PDA的发展,而Dectin-1缺失则具有保护作用。此外,我们发现,
半乳糖凝集素-9是一种对β-半乳糖苷具有亲和力的凝集素,在PDA肿瘤微环境中普遍存在,
连接Dectin-1。从机制上讲,我们发现肿瘤相关巨噬细胞(TAMs)中的Dectin-1信号转导
诱导其重编程为免疫抑制性M2样巨噬细胞,导致Th 2和Treg
体内CD 4 + T细胞的分化。基于这些数据,我们假设半乳糖凝集素-9的Dectin-1连接是
驱动胰腺TME中免疫抑制的枢轴开关。在目标1中,我们将确定
在PDA中Dectin-1激活的后果,并测试靶向Dectin-1或半乳糖凝集素-9是否具有保护性,
延长多种PDA小鼠模型的存活率。我们还将确定特定的隔室(上皮与
炎症),其中Dectin-1信号传导是致癌的。在目标2中,我们将测试我们的首要假设是,
骨髓细胞Dectin-1信号转导诱导免疫抑制性巨噬细胞亚群的差异扩增
其具有产生导致肿瘤容许性无反应性的促肿瘤发生T细胞的倾向。我们也将
描述了PDA中Dectin-1依赖性适应性免疫无能的生化机制,并测试了我们的
翻译假说,靶向Dectin-1将与检查点受体定向的
免疫方案。总的来说,目标2将定义Dectin的细胞和生化机制,
1促进PDA的发展,并为开发新的实验治疗策略提供指导。
目的3将致力于阐明Dectin-1信号在人PDA中的免疫抑制作用,
研究Dectin-1-Galectin-9轴对获得性免疫抑制和临床的影响,
患者的病理疾病特征和结果。我们预计,通过半乳糖凝集素-9激活Dectin-1是一种有效的方法。
PDA中免疫抑制性骨髓细胞编程的主要驱动因素,导致CD 4+和CD 8 + T细胞无反应性。
我们相信我们的工作具有很高的翻译价值,并将表明Dectin-1和Galectin-9可能具有吸引力
用于患者的实验性治疗。而且,这项工作很可能对一个角色产生深远的影响
Dectin-1在其他癌症亚型和无菌性炎症中的作用。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(4)
Targeting the Atf7ip-Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity.
- DOI:10.1158/2326-6066.cir-21-0543
- 发表时间:2021-11
- 期刊:
- 影响因子:10.1
- 作者:Hu, Hai;Khodadadi-Jamayran, Alireza;Dolgalev, Igor;Cho, Hyunwoo;Badri, Sana;Chiriboga, Luis A.;Zeck, Briana;Gregorio, Miguel Lopez De Rodas;Dowling, Catriona M.;Labbe, Kristen;Deng, Jiehui;Chen, Ting;Zhang, Hua;Zappile, Paul;Chen, Ze;Ueberheide, Beatrix;Karatza, Angeliki;Han, Han;Ranieri, Michela;Tang, Sittinon;Jour, George;Osman, Iman;Sucker, Antje;Schadendorf, Dirk;Tsirigos, Aristotelis;Schalper, Kurt A.;Velcheti, Vamsidhar;Huang, Hsin-yi;Jin, Yujuan;Ji, Hongbin;Poirier, John T.;Li, Fei;Wong, Kwok-Kin
- 通讯作者:Wong, Kwok-Kin
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAFNA BAR-SAGI其他文献
DAFNA BAR-SAGI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAFNA BAR-SAGI', 18)}}的其他基金
A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.
一种治疗突变型 KRas 胰腺癌的新型单体药物缀合物。
- 批准号:
10666997 - 财政年份:2022
- 资助金额:
$ 38万 - 项目类别:
A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.
一种治疗突变型 KRas 胰腺癌的新型单体药物缀合物。
- 批准号:
10323748 - 财政年份:2021
- 资助金额:
$ 38万 - 项目类别:
A novel monobody-drug conjugate to treat mutant Ras multiple myeloma
一种治疗突变 Ras 多发性骨髓瘤的新型单体药物偶联物
- 批准号:
10080987 - 财政年份:2020
- 资助金额:
$ 38万 - 项目类别:
Dectin-1 signaling drives pancreatic oncogenesis by inducing macrophage-mediated adaptive immune suppression
Dectin-1 信号传导通过诱导巨噬细胞介导的适应性免疫抑制来驱动胰腺肿瘤发生
- 批准号:
10054171 - 财政年份:2017
- 资助金额:
$ 38万 - 项目类别:
Oncogenic Ras-induced macropinocytosis: A new paradigm for metabolic adaptation
致癌 Ras 诱导的巨胞饮作用:代谢适应的新范例
- 批准号:
10208796 - 财政年份:2016
- 资助金额:
$ 38万 - 项目类别:
Oncogenic Ras-induced macropinocytosis: A new paradigm for metabolic adaptation
致癌 Ras 诱导的巨胞饮作用:代谢适应的新范例
- 批准号:
9348606 - 财政年份:2016
- 资助金额:
$ 38万 - 项目类别:
Oncogenic Ras-induced macropinocytosis: A new paradigm for metabolic adaptation
致癌 Ras 诱导的巨胞饮作用:代谢适应的新范例
- 批准号:
9979778 - 财政年份:2016
- 资助金额:
$ 38万 - 项目类别:
Oncogenic Ras-induced macropinocytosis: A new paradigm for metabolic adaptation
致癌 Ras 诱导的巨胞饮作用:代谢适应的新范例
- 批准号:
10430204 - 财政年份:2016
- 资助金额:
$ 38万 - 项目类别:
Oncogenic Ras-induced macropinocytosis: A new paradigm for metabolic adaptation
致癌 Ras 诱导的巨胞饮作用:代谢适应的新范例
- 批准号:
9190721 - 财政年份:2016
- 资助金额:
$ 38万 - 项目类别:
Research Training for Physician-Scientists in Gastrointestinal Oncology
胃肠肿瘤学医师科学家研究培训
- 批准号:
10478062 - 财政年份:2015
- 资助金额:
$ 38万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 38万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 38万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 38万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 38万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 38万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 38万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 38万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 38万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 38万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 38万 - 项目类别:
Continuing Grant